EU approves use of Humira (adalimumab)in children with Plaque Psoriasis-AbbVie
AbbVie announced that the European Commission (EC) has granted marketing authorization for Humira (adalimumab) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. With the EC decision, Humira now has approval for use in this indication in all member states of the European Union.
The marketing authorization is based on the positive results of a Phase III study, which will be presented at an upcoming medical meeting.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.